Seres Therapeutics Inc
MCRB14.621USD
+0.631+4.51%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
6.38MCap. mercado
0.09P/E TTM
Más Datos de Seres Therapeutics Inc Compañía
Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. The Company is engaged in developing SER-155, which has demonstrated a significant reduction in bloodstream infections and related complications (as compared to placebo) in a clinical study in patients undergoing allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT). The Company is also advancing additional cultivated oral live biotherapeutics for medically vulnerable populations, including those with chronic liver disease, cancer neutropenia, and solid organ transplants. The Company's clinical and nonclinical data across its programs support the development of live biotherapeutics to target the prevention and treatment of a broad swath of infections, and in inflammatory and immune diseases.
Información de la empresa
Símbolo de cotizaciónMCRB
Nombre de la empresaSeres Therapeutics Inc
Fecha de salida a bolsaJun 26, 2015
Director ejecutivoMr. Thomas J. DesRosier, J.D.
Número de empleados103
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 26
Dirección101 Cambridge Park Drive
CiudadCAMBRIDGE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02140
Teléfono16179459626
Sitio Webhttps://www.serestherapeutics.com/
Símbolo de cotizaciónMCRB
Fecha de salida a bolsaJun 26, 2015
Director ejecutivoMr. Thomas J. DesRosier, J.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Thomas J. DesRosier, J.D.
Mr. Thomas J. DesRosier, J.D.
Co-President, Co-Chief Executive Officer, Chief Legal Officer, Secretary
Co-President, Co-Chief Executive Officer, Chief Legal Officer, Secretary
7.29K
+2.32%
Dr. Matthew R. Henn, Ph.D.
Dr. Matthew R. Henn, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
4.38K
+3.81%
Mr. Richard N. Kender
Mr. Richard N. Kender
Independent Director
Independent Director
3.17K
--
Dr. Teresa L. Young, Ph.D.
Dr. Teresa L. Young, Ph.D.
Executive Vice President, Chief Commercial and Strategy Officer
Executive Vice President, Chief Commercial and Strategy Officer
--
--
Mr. Paul R. Biondi
Mr. Paul R. Biondi
Independent Director
Independent Director
--
--
Mr. Stephen A. Berenson
Mr. Stephen A. Berenson
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
--
--
Dr. Claire M. Fraser, Ph.D.
Dr. Claire M. Fraser, Ph.D.
Independent Director
Independent Director
--
--
Dr. Hans-Juergen Woerle, M.D., Ph.D.
Dr. Hans-Juergen Woerle, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Marella Thorell
Ms. Marella Thorell
Co-President, Co-Chief Executive Officer, Chief Financial Officer
Co-President, Co-Chief Executive Officer, Chief Financial Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Thomas J. DesRosier, J.D.
Mr. Thomas J. DesRosier, J.D.
Co-President, Co-Chief Executive Officer, Chief Legal Officer, Secretary
Co-President, Co-Chief Executive Officer, Chief Legal Officer, Secretary
7.29K
+2.32%
Dr. Matthew R. Henn, Ph.D.
Dr. Matthew R. Henn, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
4.38K
+3.81%
Mr. Richard N. Kender
Mr. Richard N. Kender
Independent Director
Independent Director
3.17K
--
Dr. Teresa L. Young, Ph.D.
Dr. Teresa L. Young, Ph.D.
Executive Vice President, Chief Commercial and Strategy Officer
Executive Vice President, Chief Commercial and Strategy Officer
--
--
Mr. Paul R. Biondi
Mr. Paul R. Biondi
Independent Director
Independent Director
--
--
Mr. Stephen A. Berenson
Mr. Stephen A. Berenson
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Desglose de ingresos
FY2023
FY2022
FY2021
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
United States
126.33M
0.00%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 17 de may
Actualizado: sáb., 17 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Flagship Ventures
13.24%
Fidelity Management & Research Company LLC
12.51%
Nestle SA
12.47%
The Vanguard Group, Inc.
3.49%
BlackRock Institutional Trust Company, N.A.
0.96%
Other
57.33%
Accionistas
Accionistas
Proporción
Flagship Ventures
13.24%
Fidelity Management & Research Company LLC
12.51%
Nestle SA
12.47%
The Vanguard Group, Inc.
3.49%
BlackRock Institutional Trust Company, N.A.
0.96%
Other
57.33%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
19.23%
Venture Capital
13.24%
Corporation
12.47%
Investment Advisor/Hedge Fund
1.46%
Research Firm
1.04%
Individual Investor
0.59%
Hedge Fund
0.45%
Bank and Trust
0.05%
Other
51.47%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
284
4.24M
48.53%
-1.00M
2025Q1
303
4.22M
48.29%
-1.11M
2024Q4
311
85.93M
50.33%
-20.68M
2024Q3
330
86.09M
50.57%
-26.54M
2024Q2
336
69.70M
45.95%
-51.91M
2024Q1
345
94.53M
65.81%
-35.72M
2023Q4
345
98.23M
75.49%
-30.72M
2023Q3
356
117.05M
93.47%
-19.47M
2023Q2
384
121.97M
97.71%
-18.66M
2023Q1
378
115.00M
93.33%
-29.90M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Flagship Ventures
1.16M
13.24%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
1.09M
12.51%
+2.16K
+0.20%
Mar 31, 2025
Nestle SA
1.09M
12.47%
+709.39K
+186.83%
Sep 30, 2024
The Vanguard Group, Inc.
304.60K
3.49%
+10.91K
+3.71%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
84.10K
0.96%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
80.94K
0.93%
+5.42K
+7.17%
Mar 31, 2025
Bank Vontobel AG
54.30K
0.62%
+7.38K
+15.74%
Mar 31, 2025
UBS Financial Services, Inc.
69.22K
0.79%
+52.11K
+304.43%
Mar 31, 2025
Charles Schwab Investment Management, Inc.
41.70K
0.48%
-1.59K
-3.66%
Mar 31, 2025
Susquehanna International Group, LLP
35.86K
0.41%
+19.47K
+118.77%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
iShares Micro-Cap ETF
0.01%
Invesco RAFI US 1500 Small-Mid ETF
0%
Direxion Daily S&P Biotech Bull 3X Shares
0%
iShares Russell 2000 Growth ETF
0%
iShares Biotechnology ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
FlexShares Morningstar US Market Factor Tilt Index Fund
0%
Proshares Ultra Russell 2000
0%
Ver más
iShares Micro-Cap ETF
Proporción0.01%
Invesco RAFI US 1500 Small-Mid ETF
Proporción0%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0%
iShares Russell 2000 Growth ETF
Proporción0%
iShares Biotechnology ETF
Proporción0%
Invesco Nasdaq Biotechnology ETF
Proporción0%
ProShares Hedge Replication ETF
Proporción0%
iShares Russell 2000 ETF
Proporción0%
FlexShares Morningstar US Market Factor Tilt Index Fund
Proporción0%
Proshares Ultra Russell 2000
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
